Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Toray Industries, Inc
Age
40–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Clinical, radiographic, and histologic features consistent with the diagnosis of IPF
SpO2 ≥90% at rest by pulse oximetry while breathing ambient air.
FVC ≥50% of predicted.
FEV1 ≥50% of predicted.
Ratio of FEV1 to FVC ≥0.7.
DLCO corrected for hemoglobin 30% to 79% of predicted, inclusive.
You may not be if
History of acute exacerbation of IPF or respiratory tract infection within 3 months prior to Screening.
Planned surgery during the study.
History of malignant tumor within 5 years prior to Screening.
History of emphysema or clinically significant respiratory diseases (other than IPF).
Other known causes of interstitial lung disease (eg, drug toxicities, environmental exposures, connective tissue diseases).
End-stage fibrotic disease expected to require organ transplantation within 6 months.
Taking a systemic corticosteroid, cytotoxic therapy, vasodilator therapy for pulmonary hypertension, or unapproved treatment for IPF within 4 weeks prior to Screening. (Treatment with pirfenidone or nintedanib, though not both concurrently, is permitted, provided that the subject has been on a stable dose for at least 4 weeks prior to Screening and it is anticipated the dose will remain unchanged throughout enrollment.)
